Sonia Burgaz

Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

Concepción García, María Gómez‐Cañas, Sonia Burgaz et al. · Journal of Neuroinflammation · 2018 · 62 citations · Full text

Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

Isabel Espadas, Ettel Keifman, Cristina Palomo‐Garo et al. · Neurobiology of Disease · 2020 · 42 citations · Full text

Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease

Sonia Burgaz, Concepción García, María Gómez‐Cañas et al. · Molecules · 2019 · 34 citations · Full text

Experimental Parkinson ’, Experimental Pharmacology, Oral Vce-003.2 +22

Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice

Sonia Burgaz, Concepción García, María Gómez‐Cañas et al. · Molecular and Cellular Neuroscience · 2020 · 31 citations

6-Hydroxydopamine-lesioned Mice, Medicine, Neuropharmacology +7

Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease

Sonia Burgaz, Concepción García, María Gómez‐Cañas et al. · Molecules · 2021 · 28 citations · Full text